Providers

HCP header

Share this page

Twitter icon
Facebook icon
Google icon
Pinterest icon
e-mail icon

Send Me Updates

Email opt-in for providers use only, not intended for patient use.

 

 

 

 

About Panorama™

 

Panorama is a non-invasive prenatal screening test (NIPT) for fetal chromosomal abnormalities. The test uses advanced bioinformatics technology to evaluate fetal (of placental origin) DNA in maternal blood.

Only Panorama can distinguish between fetal and maternal DNA in the mother's blood to give you and your patient vital information about the fetus. With a comprehensive panel of chromosomal aneuploidies and microdeletions, Panorama delivers the most accurate results of any screening test, as early as 9 weeks of gestation, to help you manage your patient's pregnancy.

Meet your local Clinical Specialist

 Locate

Choose Panorama

You and your patients deserve the reassurance that comes from using a prenatal screening test with the highest combined accuracy across a broad panel of genetic conditions.

Powered by the most advanced bioinformatics technology. the Panorama™ test provides personalized risk scores for aneuploidy at chromosomes 13, 18, 21, X and Y, triploidy, and microdeletions with the highest combined accuracy in published clinical trials. 

The benefits of Panorama are VAST:

Vanishing Twin: Only Panorama can distinguish if a vanishing twin's DNA is still present in maternal circulation. The presence of DNA from a vanishing twin cannot be detected using other NIPT methods and can result in an increase in false positive or false negative test results.

Analysis of the maternal contribution: Only Panorama evaluates the maternal genotype in addition to the fetal genotype, thereby providing a clearer result on the pregnancy.

Sex chromosome assessment: Gender determination has shown >99% accuracy in clinical studies. In addition, Panorama will report sex chromosome trisomies when seen (47 XXX, 47 XXY, 47 XYY).

Triploidy: Only Panorama can detect triploidy as well as provide a risk assessment on every report. This assessment can be beneficial when ultrasound findings are suggestive of triploidy, or for couples seeking recurrence risk assessment following a previous pregnancy with triploidy.    

Panorama builds on this technology to provide high sensitivity rates even at low fetal fraction.

Compare Your Options

The Most Accurate

Panorama™ provides risk assessment on more clinically significant chromosome abnormalities than other NIPTs. Every Panorama report includes a personalized risk score for trisomy 21, 18, 13, monosomy X, and triploidy.

In addition, Panorama offers a panel of microdeletion syndromes. These syndromes were chosen with care to provide relevant information for conditions that are common, can be severe, are under-diagnosed prenatally, and may benefit from early intervention after delivery.

 

Clinical Data

 

 

 

 

 

 

With unparalleled accuracy for trisomy 21 and fetal sex in validation studies, Panorama™ demonstrates >99% combined sensitivity and specificity.

 

 

 

 

 

 

 

 

 

Fetal Fraction

 

 

 

 

Up to 1/3 of all NIPT cases have <8% fetal fraction, which is often associated with decreased sensitivity. Panorama measures fetal fraction and adjusts its algorithm accordingly to improve sensitivity even at low fetal fractions. We report fetal fraction for all cases, providing you reliable information as you counsel your patients.

 

 

 

 

 

Minimal False Negatives

 

 

 

 

 

 

 

Low fetal fraction is one of the most common causes of false negative results.

Panorama has the lowest false negative rate, 0.7%, in published clinical trials. 

Panorama measures fetal fraction and adjusts the algorithm accordingly to improve sensitivity even at low fetal fractions.

 

 

 

 

 

 

 

 

Fetal Sex

 

 

 

 

 

With 100% correct gender reported in validation studies, Panorama gives you and your patients peace of mind.

 

 

 

 

 

 

Maternal Contribution

Maternal abnormalities, such as maternal mosaicism, can contribute to false positive results with NIPT tests that cannot distinguish between fetal and maternal DNA. In fact, maternal mosaicism led to 8.6% of false positive results when screening sex chromosomes with other NIPT tests [reference: Wang Y et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clinical Chemistry 2014; 60(1):251-9.]

For example, as women age, some of their cells begin to lose the X chromosome, as shown on the chart to the left. As a result, NIPT tests may incorrectly report Monosomy X because they detect a lower than expected amount of the X chromosome in maternal plasma. As the only NIPT test that distinguishes between fetal and maternal DNA, Panorama accurately detects fetal chromosomal abnormalities, even in the presence of maternal mosaicism. 

 

How Panorama works


Panorama™ is the only non-invasive prenatal screening test that distinguishes between fetal and maternal cell-free DNA thanks to SNP-based sequencing and Natera's proprietary Natus™ (Next-Generation Aneuploidy Test Using SNPs) algorithm.

For more information on Panorama, click below to download a copy of either of our whitepapers: 

Non-Invasive Prenatal Testing: The New Panorama Test and Panorama™ Non-Invasive Prenatal Screening for Microdeletion Syndromes.

Non-Invasive Prenatal Testing: The New Panorama™ Test

Order Kits

Talk to your patients about Panorama™

Evidence supports the use of NIPT as the first line screen for all pregnancies, regardless of risk.

 

 Sources